Pfizer, Fauci staffers sign off on research finding mRNA COVID vaccines produce worse antibodies
Second study in a month to find "class switch" to so-called IgG4 antibodies, known for their mild immune response, in mRNA recipients alone. Future of Johnson & Johnson's traditional vaccine unclear as demand craters.